Impax Laboratories — Q4 2017 Earnings Presentation
23 slides from Impax Laboratories's earnings presentation, Mar 1, 2018
Slide 1: Fourth Quarter and Full Year 2017 Results
1 Fourth Quarter and Full Year 2017 Results March 1, 2018
Slide 2: Cautionary Statement Regarding Forward Looking Statements
2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and
Slide 3: Important Information for Investors and Shareholders
3 Important Information for Investors and Shareholders Additional Information and Where to Find It This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. This communication may be deemed to be solicitat
Slide 4: Paul Bisaro, President & CEO
mead Paul Bisaro President & CEO
Slide 5: 4Q and Full Year 2017 Financial Summary
5 4Q and Full Year 2017 Financial Summary $ millions, except EPS 4Q 2017 4Q 2016 FY 2017 FY 2016 Total Revenues, net $183 $198 $776 $824 Generic, net $113 $139 $549 $606 Specialty, net $70 $59 $227 $218 Adjusted Gross Margin 50% 47% 49% 50% Adjusted EBITDA $33 $37 $150 $200 Adjusted EPS $0.11 $0.16
Slide 6: 2017 Initiatives
6 2017 Initiatives Original Timing Updated Timing Consolidation of all generic R&D to Hayward, CA Completed mid-2017 Completed on-time Closure of Middlesex packaging site Completion by end of 1Q18 Completed end of 2017 Strategic alternatives for Taiwan manufacturing site As late as end of 2019 Compl
Slide 7: Strategic Combination for Long-Term Growth
7 Strategic Combination for Long-Term Growth (1) Per Last Twelve Months IMS Gross Revenues as of June 2017. (2) Includes expected Year 1 run-rate synergies. (3) In addition to the previously announced Impax standalone cost savings initiatives. Expanded Portfolio to Drive Growth Creates 5th largest
Slide 8: Transaction Timeline
8 Transaction Timeline Pre-close integration planning well underway Enhanced leadership team of combined company Regulatory review process progressing as expected Impax shareholder meeting March 27, 2018 to approve combination Developing debt structure to maximize flexibility and maintain low
Slide 9: 2017 Achievements
9 35 new products launched 36 ANDAs approved; 9 tentatively approved 48 ANDAs filed Launched traimcinolone injection (first generic) Launched thiotepa 15mg and 100mg injection (only 100mg product available) Launched gAggrenox capsules and mometasone nasal spray Filgrastim (NeupogenTM)
Slide 10: Solid Start to 2018
10 6 generic products approved 5 generic products launched including: gConcerta® 18 mg, 27 mg, 36 mg and 54 mg gAccutane® 10 mg, 20 mg, 30 mg and 40 mg gEntocort® EL 3 mg gNamenda XR® 7 mg, 14 mg, 21 mg and 28 mg gTamiflu oral suspension 6 mg/ml Amneal Impax Launched authorized gener
Slide 11: Bryan Reasons, Chief Financial Officer
11 Bryan Reasons Chief Financial Officer
Slide 12: Generic Division 4Q 2017 Results
12 Generic Division 4Q 2017 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results. $ millions 4Q 2017 3Q 2017 Change 4Q/3Q 4Q 2016 Change 4Q/4Q Total Revenues, net $112.9 $151.1 (25%) $139.2 (19%) GAAP Gross Margin (34%) (2%) -- (127%) -
Slide 13: Specialty Pharma Division 4Q 2017 Results
13 Specialty Pharma Division 4Q 2017 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results. $ millions 4Q 2017 3Q 2017 Change 4Q/3Q 4Q 2016 Change 4Q/4Q Total Revenues, net $70.0 $55.3 27% $59.2 18% GAAP Gross Margin 72% 68% -- 26% -- Ad
Slide 14: Selected 4Q 2017 Non-GAAP Adjustments
14 Selected 4Q 2017 Non-GAAP Adjustments $ millions 4Q 2017 Related to: Intangible Asset Impairment Charges $231 In-process R&D (gConcerta® and QVAR®) and two marketed products acquired in 2016 Change in Fair Value of Contingent Consideration ($38) Reduction in milestone liability related to delayed
Slide 15: Consolidated 4Q 2017 Results
15 Consolidated 4Q 2017 Results Refer to the GAAP to non-GAAP reconciliation tables in the appendix for a reconciliation of non-GAAP results. $ millions, except per share amounts 4Q 2017 3Q 2017 Change 4Q/3Q 4Q 2016 Change 4Q/4Q EBITDA ($274.8) ($15.4) (1,684%) ($234.0) (17%) Adjusted EBITDA $33.1 $
Slide 16: Paul Bisaro, President & CEO
16 Paul Bisaro President & CEO
Slide 17: Path Forward
17 Position New Amneal For Sustainable Long-Term Growth • Generics: Continuing internal R&D investment focused on all seven dosage forms • Specialty: Continuing focus on Movement Disorders pipeline and opportunistically in-license external opportunities INVEST IN ORGANIC GROWTH • Maintain high level
Slide 18: Q&A
18 Q&A
Slide 19: GAAP to Adjusted Results Reconciliation
19 GAAP to Adjusted Results Reconciliation The following table reconciles total Company reported cost of revenues to adjusted cost of revenues, adjusted gross profit, adjusted gross margin, adjusted research and development expenses, and adjusted selling, general and administrative expenses. Refer t
Slide 20: GAAP to Adjusted Net Income Reconciliation
20 GAAP to Adjusted Net Income Reconciliation The following table reconciles reported net loss to adjusted net income. Refer to the Fourth Quarter and Full Year 2017 Earnings Release for an explanation of adjusted items. The sum of the individual amounts may not equal due to rounding. Three Months E
Slide 21: GAAP to Adjusted EBITDA Reconciliation
21 GAAP to Adjusted EBITDA Reconciliation Refer to the Fourth Quarter and Full Year 2017 Earnings Release for an explanation of adjusted items. The sum of the individual amounts may not equal due to rounding. The following table reconciles reported net loss to adjusted EBITDA. Three Months Ended Yea
Slide 22: Generic Division GAAP to Adjusted Results Reconciliation
22 Generic Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Generics Division reported cost of revenues and loss from operations to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted operating income. Refer to the Fourth Quar
Slide 23: Specialty Pharma Division GAAP to Adjusted Results Reconciliation
23 Specialty Pharma Division GAAP to Adjusted Results Reconciliation The following tables reconcile the Impax Specialty Pharma Division reported cost of revenues and (loss) income from operations to adjusted cost of revenues, adjusted gross profit, adjusted gross margin and adjusted income from oper